Exelixis | EXEL - Current Liabilities



Exelixis reported $336.11M in Current Liabilities for its fiscal quarter ending in July of 2025.


Current Liabilities Change Date
Acadia Pharmaceuticals USD 330.02M 27.49M Jun/2025
Agios Pharmaceuticals USD 70.41M 18.04M Jun/2025
Amgen USD 20.48B 2.53B Jun/2025
AstraZeneca USD 33.54B 4.41B Jun/2025
Bayer EUR 29.78B 1.82B Jun/2025
BioMarin Pharmaceutical USD 684.25M 56.03M Jun/2025
Bristol-Myers Squibb USD 27.53B 3.46B Jun/2025
Cytokinetics USD 131.06M 28.66M Jun/2025
Eisai JPY 411.61B 39.31B Jun/2025
Eli Lilly USD 39.02B 8.95B Jun/2025
Exelixis USD 336.11M 62.99M Jul/2025
Genmab DKK 629M 127M Jun/2025
Glaxosmithkline GBP 20.38B 1.32B Jun/2025
Incyte USD 1.28B 608.18M Jun/2025
Ionis Pharmaceuticals USD 897.24M 646.94M Jun/2025
MacroGenics USD 39M 16.53M Jun/2025
Merck USD 26.04B 863M Jun/2025
Moderna USD 1.57B 32M Jun/2025
Neurocrine Biosciences USD 546.3M 23.4M Jun/2025
Novartis USD 31.71B 95M Jun/2025
Pfizer USD 37.73B 1.27B Jun/2025
Sanofi 29.06B 103M Jun/2025
Takeda JPY 2.17T 336.94B Jun/2025
Ultragenyx Pharmaceutical USD 293.24M 1.58M Jun/2025
Xencor USD 96.08M 7.65M Jun/2025